NTLA biotech catalysts & pipeline

INTELLIA THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

lonvoguran ziclumeran (also referred to as NTLA-2002) — Filing acceptance

H2 2026

Intellia expects the U.S. Food and Drug Administration (FDA) to accept its submission of a biologics license application (BLA) for lonvo-z in the second half of 2026.

Source filing

lonvo-z — NDA/BLA submission

H1 2027

Rolling biologics license application (BLA) submission initiated with the U.S. Food and Drug Administration (FDA); anticipate U.S. launch in the first half of 2027, if approved

Source filing

lonvoguran ziclumeran (also referred to as NTLA-2002) — Regulatory decision

H1 2027

The company continues to anticipate regulatory approval and a U.S. launch in the first half of 2027.

Source filing

nexiguran ziclumeran (also referred to as NTLA-2001) — NDA/BLA submission

by 2028

Intellia anticipates submitting a biologics license application (BLA) for ATTRv-PN by 2028.

Source filing

Explore the free biotech catalyst calendar